Inflammation: The next frontier in ASCVD care
Tuesday 28 May 2024 | 45 minutes, 13:45 – 14:30 CEST
We are excited to inform you about the Novo Nordisk Symposium at EAS 2024, entitled “Inflammation: The next frontier in ASCVD care”. During this symposium, our expert faculty Philippe Moulin, Peter Libby, Lale Tokgözoğlu, and Viviane Zorzanelli Rocha Giraldez will discuss the drivers of atherosclerotic cardiovascular disease (ASCVD) risk, the role of interleukin-6 in the pathogenesis of ASCVD and review the current evidence on the use of anti-inflammatory therapies for reducing cardiovascular risk in patients with ASCVD and chronic kidney disease. They will also explore the clinical utility of hsCRP as a biomarker for systemic inflammation before delving into the future of anti-inflammatory therapy. Attendees will have the opportunity to ask questions to the faculty in a live Q&A session at the end of the symposium.
On behalf of the faculty, we look forward to welcoming you onsite or online for an informative and engaging session.
